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THE HUMAN cardiac Na channel gene SCN5A encodes the ion channel hNa v 1.5 (9) , which carries inward Na current (I Na ) in heart. Mutations in SCN5A cause arrhythmia syndromes including congenital long QT syndrome LQT3 and Brugada syndrome (2, 12) . Two distinct full-length hNa v 1.5 clones isolated from human cardiac cDNA libraries, hH1 (8) and hH1a (10) , have been used previously to characterize human I Na for wild-type channels and for channels containing putative arrhythmia-causing mutations. The sequences for hH1 and hH1a reportedly differ in 9 of the 2,016 amino acids (8, 10) and have never been studied under identical conditions. We hypothesized that these differences might affect function, either of wild-type channels, or when arrhythmia mutations were inserted into the different backgrounds. For this study, RT-PCR was used to obtain a third complete clone (designated hH1b) for hNa v 1.5. hH1b contained a known common polymorphism H558R whereby histidine (H) at position 558 is replaced by an arginine (R) (11, 17) . We also studied an LQT3 mutation M1766L that was previously reported to have both decreased current expression and at the same time enhanced late current (relative to peak current) when expressed in the hH1a background (14) . In the present study, I Na expression for the M1766L mutation expressed in the three background clones depended upon the polymorphism at position 558. Thus SCN5A serves as its own modifier gene. These results represent a novel form of "intragenic complementation" where a mutation at one locus in a gene interacts with a mutation at another locus to restore function of the gene product. This striking observation also raises the question: What is the correct background Na channel clone to use for the study of LQTS, Brugada syndrome, or SIDS-causing mutations within SCN5A?
(accession no. AF482988). The complete clone was pulled out in two overlapping pieces and was sequenced completely three times for verification. PCR cloning differs from the usual method of creating a cDNA library. No claim is made that the clone obtained by this method is more accurate than the previous clones, only that it is a third independent clone.
Gene expression and mutagenesis. The Na v1.5 clones, hH1 [kindly provided by Dr. Al George (8), GenBank accession no. M77235] in prcCMV (Invitrogen) and hH1a [kindly provided by Dr. H. Hartmann (10) ] and hH1b in pcDNA3 (Invitrogen), were expressed in HEK293 cells. The amino acid numbering follows that of the original hH1 clone comprising 2,016 amino acids. The transfections were performed with Superfect (Qiagen, Valencia, CA) according to the manufacturer's recommended protocol. A GFP protein was cotransfected (at 1:10) as a marker to identify the transfected cells. HEK293 cells were harvested 24 h after transfection to measure macroscopic current. HEK293 cells were cultured as previous described (13) . Mutations were generated using an Excite mutagenesis kit (Stratagene, La Jolla, CA). The method for mutagenesis was based on the manufacturer's suggested protocol. The M1766L mutation was created with 5Ј TTC CTC ATC GTG GTT AAC CTG TAC ATT GCC ATC 3Ј and 5Ј GGA GAT GAT GAT GTA GGT GG 3Ј primers. The histamine-to-arginine substitution at position 558 was generated with 5Ј C GAG AGC CAC CGC GCA TCA CTG CTG 3Ј and 5Ј CT CTC CCC CGC TGT GCT GTT TTC 3Ј primers. DNA was isolated and purified with the Qiagen column and protocol. After mutagenesis the clone was resequenced to verify that the mutation was made as designed.
Immunocytochemistry. The FLAG epitope was introduced between S1 and S2 in domain I (DI) for the immunocytochemistry experiments. Transfected and nontransfected HEK293 cells were fixed with 4% paraformaldehyde at room temperature for 20 min. The fixed cells were blocked with 5% goat serum and 0.2% Triton PBS solution at room temperature for 30 min. After the blocking procedure, the cells were incubated with the mouse anti-FLAG M2 primary antibody (Stratagene) at the ratio of 1:2,000 overnight at 4°C. On the next day, the cells were washed with PBS before 1:100 fluorescein-conjugated goat anti-mouse antibody (Jackson, West Grove, PA) was applied as the secondary antibody and allowed to react for 1 h at room temperature in the dark. The cells were washed with PBS solution and fixed with a solution containing 90% glycerol and 10% sodium bicarbonate. A Bio-Rad MRC 1024 laser scanning system with 15 mW mixed gas (krypton/argon) laser was utilized to view immunofluorescent labeled cell. The Bio-Rad MRC 1024 system was mounted on a Nikon Diaphot 200 inverted microscope. Images of the fluorescent-labeled cells were scanned under a ϫ40 objective with normal speed, ϫ2 zoom. The confocal system was set to 3.6 for iris, laser power at 100%, and camera sensitivity gain to 900. A Kalman collection filter with 5 frames per image was applied to record the image.
Voltage clamp techniques. Details of the whole cell patchclamp technique to measure macroscopic INa including late INa have been previously published (13) . The bath (extracellular) solution contained (in mM) 140 NaCl, 4 KCl, 1.8 CaCl2, 0.75 MgCl2, and 5 HEPES (pH 7.4 set with NaOH). The pipette (intracellular) solution contained (in mM) 120 CsF, 15 CsCl, 2 EGTA, 5 HEPES, and 5 NaCl (pH 7.4 with CsOH). Data was recorded at room temperature using pCLAMP 8 (Axon Instruments Foster City, CA). Voltage clamp protocols are presented with the data.
Data analysis. Peak INa and late INa were obtained after passive leak subtraction as described previously (13) . Activation and inactivation data were fitted to a standard Boltzmann equation using Clampfit 8 (Axon Instrument) and recovery and decay data to a two-exponential equation. The equations used are the same as Nagatomo et al. (13) . Goodness of fit was determined both visually and by a sum of squares errors. One-way ANOVA was performed to determine statistical significance among three or more groups of mean data. Statistical significance was determined by P Ͻ 0.05.
RESULTS
Amino acid differences in the three complete hNa v 1.5 clones. We generated a third complete hNa v 1.5 clone (hH1b) from human heart mRNA using RT-PCR. The hH1b clone was sequenced, and the two existing hNa v 1.5 clones (hH1 and hH1a) were resequenced completely. The previously reported sequences for hH1 and hH1a differ by nine amino acids with hH1 also containing one additional amino acid (glutamine at residue 1077, Q1077). Upon resequencing hH1, we found that seven amino acids in hH1 differed from the published sequence for hH1 (V120I, A180G, R552G, H987Q, W1085G, R1087E, and G1088A, where the second letter represents the resequenced amino acid). On the other hand, resequencing hH1a confirmed the originally published sequence. Each of the seven amino acid changes in the resequenced hH1 agreed with the hH1a sequence, reducing the difference between these clones to just three amino acids (T559 vs. A559, Q1027 vs. R1027, and Q1077 vs. Q1077del, between hH1 and hH1a, respectively, see Table 1 ). These residues are confined to the DI-II and DII-III cytoplasmic linkers ( Fig. 1 ). Both hH1 and hH1a contain a histidine residue at amino acid 558 (H558), a site hosting the common polymorphism (H558R) (11, 17) .
The new clone, hH1b, reported here differed from hH1 by four amino acids, R558 vs. H558, I618 vs. L618, R1027 vs. Q1027, and Q1077del vs. Q1077 (hH1b vs. hH1, respectively), in the DI-II and DII-III linker, and from hH1a by three amino acids, R558 vs. H558, T559 vs. A559, and I618 vs. L618 (hH1b vs. hH1a, respectively), confined to the DI-II linker (Table 1) . Results from Blast searching of the human genome sequence at Celera database showed only two differences between hH1b and Celera (R558 vs. H558 and I618 vs. L618, Table 1 ) confined to the DI-II linker (Fig. 1 ). Four additional synonymous or "silent" base differences be- 
Numbering follows the original numbering of Gellens et al. (8) for hH1. The sequence designated "Celera" is from Celera human genome database using BLAST search. For Table 1 , data from the resequenced hH1 were used. tween hH1 and hH1b were noted (for hH1 vs. hH1b, respectively, TGT vs. TGC for amino acid C280, ACA vs. ACC at amino acid T670, CTA vs. CTC at amino acid L789, and GAC vs. GAT at amino acid D1819).
Kinetic studies of three hNa v 1.5 clones. The I Na kinetics for hH1 (8) and hH1a (10) from separate studies in the literature showed only minor differences that could be attributed to different expression systems and study techniques including solutions, temperature, and protocols. Subtle differences in kinetics such as decay rates, inactivation midpoints, and late I Na , however, may be important in controlling repolarization. We studied these three clones concurrently (on the same day) under identical conditions in the same experimental patch-clamp setup. The three clones generally showed similar current time courses (Fig. 2A) . Summary data for activation, steady-state inactivation, and recovery (Fig. 2B and Table 2 ) showed minor differences. Although not identical, the parameters were only statistically different for the midpoint of inactivation for hH1 (Ϫ95 mV) vs. hH1a (Ϫ86 mV). Late I Na measured at 240 ms after the start of the depolarization was no different among the three clones (data not show).
Rescue of expression for the M1766L mutant by using the hH1b background. An arrhythmia mutation in SCN5A, M1766L, was previously found to have a greatly reduced expression level compared with wild type when expressed in the hH1a clone (14) . By sitedirected mutagenesis, the M1766L mutation was engineered into all three clones, expressed in HEK cells, and studied by voltage clamp. Examples of I Na traces (Fig. 3) show that the amount of current for the M1766L mutant channel was greatly reduced compared with wild type when expressed in hH1 and hH1a, but the current level was nearly normal when expressed in hH1b. The amplitude of late I Na measured at 650 ms for a step to Ϫ40 mV was 4.4% Ϯ 1.0 (n ϭ 3) relative to the peak I Na , similar to the late I Na amplitude found previously for M1766L in hH1a rescued by mexiletine (14) . Summary data (Fig. 4) show that for wild type, hH1b and hH1a clones generally express more I Na than the hH1 clone. Comparing the sequence variations among the three clones (Table 1) , we hypothesized that the polymorphism H558R might underlie the restoration of expression in channels containing the M1766L mutation. Again using sitedirected mutagenesis, we engineered the double-mutation M1766L/H558R in the hH1a clone. Now, rather than the 97% reduction in current expression observed previously for M1766L-hH1a (containing H558), the M1766L/H558R-hH1a clone (now containing R558) manifested a fully restored I Na density (Figs. 3 and 4) . These experiments show that the residue at position 558 in interaction with M1766L is the residue responsible for affecting expression of I Na .
We investigated defective trafficking as a possible mechanism for the failure of M1766L to express well in the hH1a background by using confocal microscopy and by imaging the Na channel labeled with the FLAG epitope (Fig. 5) . The regular bright-field images on the left in Fig. 5 show the location of the nucleus and the cell periphery, and the fluorescent images on the right show the immunolocalization of the Na channel protein. The nontransfected cell showed minimal fluorescence, whereas transfections with wild-type hH1a and hH1b showed localization at the periphery of the cell (Fig. 5, B and C) . The M1766L mutation in the hH1a background showed a perinuclear localization pattern with no peripheral expression, consistent with trapping in the endoplasmic reticulum (3). When M1766L was expressed in the hH1b clone, the normal peripheral florescent pattern was restored (Fig. 5E) . When M1766L was expressed in the modified hH1a clone now containing R558 as in hH1b rather than H558, normal trafficking to the cell periphery was also observed (Fig.  5F ). The results shown in Fig. 5 were typical for 3-5 pictures taken of nonoverlapping cells in 3 independent expression experiments. These data are consistent with the functional data (Fig. 3) and suggest a Fig. 1 . Location of amino acid differences on the linear topology of the cardiac Na channel ␣-subunit. The four homologous domains of Na channel ␣-subunit are labeled as DI, DII, DIII, and DIV, and the six transmembrane domains are labeled S1 through S6. Circles with numbers indicate the location of sequence variants between the three full-length SCN5A clones (solid circles) as noted in Table 1 . The yellow circle indicates the location of the arrhythmia mutation M1766L. The circle with an "x" denotes the common polymorphism H558R.
trafficking defect as the mechanism for the decreased current expression. M1766L represents the third documented trafficking defect for SCN5A, with the others being R1232W (3) and R1432G (4), and it is the first trafficking defective mutation for SCN5A that has been shown to be rescued by a drug.
DISCUSSION
We report a third complete sequence of the hNa v 1.5 ␣-subunit designated hH1b. Amino acid sequences for the three clones hH1, hH1a, and hH1b, together with the sequence from the Celera database, differ in up to five amino acid positions (Table 1) . A difference found only in the hH1b clone, R558 rather than H558, is also a previously reported amino acid polymorphism (11) with ϳ20-30% of white humans heterozygous for H558R in a population study (17) . A separate analysis of healthy subjects indicates that ϳ30-40% of individuals are heterozygous for H558R with no significant difference in the allelic frequency between whites and blacks (M. J. Ackerman, unpublished data). It should be noted that the term mutation refers to any heritable or spontaneous germ line (sporadic) change in DNA sequence. The term common polymorphism refers to sequence variations occurring among populations of individuals of the same or different ethnicities with a certain allelic frequency (usually Ͼ1%) that may underlie differences in health. Clinicians and physiologists also use the term polymorphism to denote a mutation occurring with some frequency in the population that does not cause overt disease or protein dysfunction (11, 15) , which is also called a nonpathogenic mutation (15) .
Another difference found only in hH1a, A559 rather than T559, is not a known polymorphism; that is, no population studies have been done. A third difference found only in hH1b, I618 rather than L618, is also not a known polymorphism, but the conservative change of a leucine to an isoleucine is a known high-frequency spontaneous change. The fourth and fifth differences (Q1027 and Q1077) are both found only in hH1 and are not known to be polymorphisms. The latter, the insertion of Q at 1077 in hH1, occurs at an intron-exon boundary and could represent alternative splicing. Aside from the known polymorphism at position 558, the Celera sequence agrees with the "majority" and differs from hH1 at two positions (1027 and 1077), from hH1a at one position (559), and from hH1b at one position (619). These differences may be cloning errors, or they may be actual polymorphisms. Further population studies are Fig. 2 . Whole cell Na current (INa) for hH1, hH1a, and hH1b. A: representative traces were recorded with test potentials of 24-ms duration from Ϫ120 to ϩ60 mV from a holding potential of Ϫ120 mV. B: current-voltage relationship (left), "steady-state" inactivation relationship (middle), and recovery from inactivation relationship (right) for INa. Diagrams depicting the protocols are inset into each plot. In every case the test step (the second depolarization for middle and right) was 24 ms in duration. The conditioning (first) step duration for the recovery protocol was 1 s. The y-axis in each case is peak INa normalized to the maximal peak INa obtained in the protocol. Solid symbols represent the mean data for between 6 and 10 experiments (see Table 2 for exact n numbers) with hH1 (square), hH1a (circle), and hH1b (triangle), and the bars represent SD.
needed to make this determination and to more definitively determine the "correct" sequence for Na v 1.5.
We have shown that the three clones have very similar but not identical kinetic function (Table 2 and Fig. 2 ). The midpoint of inactivation was significantly more negative for hH1 (Ϫ95 mV) than it was for hH1a (Ϫ86 mV), with hH1b being in the middle (Ϫ90 mV) and not significantly different from either one within the limitations of this study. This difference has possible significance, because with the lack of difference in activation midpoint, the more positive the inactivation relationship, the more "window" current. Window current has been implicated in the control of repolarization for SCN5A mutants (1). Relatively subtle differences in the early rate of decay of I Na current may also play a role in determining repolarization by effects on other currents and the early plateau time course (6, 16) . Here caution is urged in interpretation of the voltage clamp data, as decay rates are exquisitely sensitive to voltage control problems. In our analysis, however, decay experiments were selected to have low and similar current densities with activation slopes Ͼ5.5. We conclude that the kinetic profiles are very similar but that subtle differences in the wild-type clones may be important for predisposition to arrhythmia. The differences in these channels, should they prove to be polymorphisms in the population, may be candidates for predisposition to acquired repolarization abnormalities.
The most dramatic difference between the three clones, however, is the rescue of the expression defect for M1766L when expressed in the hH1b background (Fig. 3 ) compared with hH1 and hH1a. The known polymorphism H558R and the variation L618I are the only differences between hH1 or hH1a compared with hH1b ( Table 1 ). The double mutation experiments provide strong evidence that amino acid at position 558 was responsible for the profound differences in trafficking and I Na expression level. The term "intragenic complementation" refers to the case where a mutation at one locus in a gene interacts with a mutation at another locus to restore function of the gene product. The phenomenon has been widely reported in nature, but previous examples in humans have involved small multimeric proteins where separate alleles restored enzyme function (18) . The restoration of protein function by H558R does, however, fit the original definition of intragenic complementation (7) and represents a unique example. How could amino acids located over 1,200 residues away from each other interact to restore function? Amino acids 558 and 1766 are both located intracellularly ( Fig. 1) and in theory could interact where DI and DIV come together in the folded tertiary structure. In the human enzyme argininosuccinate Fig. 3 . Current magnitude for wildtype hH1, hH1a, and hH1b clones, for the arrhythmia mutation M1766L expressed in each clone, and for the double mutation. Examples of INa traces (protocol inset) for each construct show that M1766L expressed very poorly in hH1 and hH1a but expressed normally in hH1b. Expression levels for the double-mutant M1766L/H558R in hH1a, however, were normal. The fitted kinetic parameters from n experiments were averaged and are reported as means Ϯ SD. Three SCN5A clones, hH1, hH1a, and hH1b, show minor differences in activation, inactivation and recovery from inactivation kinetics. These parameters were obtained from fitting the individual experiments as in Fig. 2 to the appropriate model equations (13) . For the Boltzmanm fits (activation and inactivation) the parameters are V1/2 midpoint and slope factor. For the double exponential fits (recovery and current decay) the parameters are: f, the fast time constant; s, the slow time constant; As, the fractional amplitude of slow component; and Af, the fractional amplitude of fast component. All parameters were analyzed by one-way ANOVA across the three clones. * Statistically significant values.
lyase, mutations at different loci on separate monomers interact to affect the thermodynamic stability of the protein (18) . Further study is required to elucidate the precise structural determinants as well as the mechanism of this restoration in hNa v 1.5.
We have shown that the "background" in which SCN5A mutations are expressed may impact profoundly the results of studies obtained in heterologous expression systems. The polymorphism also probably played a role in the pathogenesis of the arrhythmia syndrome in the patient presenting with M1766L (14) . We had previously shown that the patient had a prolonged QT interval, and that the "mexiletine-rescued" M1766L-hH1a showed a typical late I Na (14) , but we were puzzled why the patient would manifest QT prolongation in the absence of mexiletine. In light of our observation that hH1b rescued M1766L expression, we reexamined the patient's genomic DNA and found that in addition to the pathogenic mutation, M1766L, the patient was indeed heterozygous for the H558R polymorphism. Because the patient manifested QT prolongation, it might be assumed that one allele contained both R558 and L1766, resulting in a rescued Na current with increased late current. The functional evidence provided herein suggests a "double hit" requiring both mutations on the same allele. Unfortunately, no postmortem tissue permitting the isolation of SCN5A mRNA transcript from the decedent was available to confirm this speculation, only blood in EDTA preservative. Because of the large number of intervening base pairs we could not determine from the available genomic DNA whether or not they were on the same allele. Also, linkage analysis was not possible because the M1766L mutation was a spontaneous germ line mutation.
If the M1766L mutation were to reside on the more common H558-containing allele, then this would be predicted to cause loss of function and Brugada syndrome or conduction system disease. This could be one mechanism for the observation that some mutations can present with different clinical phenotypes in different persons (5) . A "double hit" involving mutations R1232W and T1620M was previously implicated to cause a trafficking defect for the Brugada syndrome (3).
Caution must always be used in extrapolating basic studies to the clinical setting. The question of whether the expression levels and the kinetic behavior of different wild-type and mutated hNa v 1.5 channels in these experimental expression systems faithfully recapitulate their function in intact heart remains a common Fig. 4 . Summary data for current density for experiments as depicted in Fig. 3 . INa values were normalized to cell capacitance, and mean values are shown as a column with SD bar, with the number of experiments indicated above the bar. To assure voltage control, cells with total currents Ͼ2 nA were excluded. Approximately 25% of wild-type currents were Ͼ2 nA and were excluded; no M1766L currents were excluded. The effect of this exclusion would tend to underestimate the INa suppression by M1766L; the actual effect is larger. limitation. Nevertheless, our findings provide a caveat for those using heterologous expression systems that the choice of background clone is important. Also our findings suggest that the particular channel background sequence in patients may be important in defining functional properties of putative arrhythmiacausing mutations in SCN5A. The search for "modifier genes" must include the disease-causing gene itself.
